Nov 17, 2025 7:00 am EST BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease
Nov 12, 2025 4:05 pm EST BioRestorative Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update
Nov 5, 2025 4:30 pm EST BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
Oct 27, 2025 7:30 am EDT BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market
Oct 22, 2025 9:35 am EDT BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio
Oct 6, 2025 2:28 pm EDT BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market
Aug 12, 2025 4:05 pm EDT BioRestorative Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update
Aug 5, 2025 4:30 pm EDT BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025